Lawrence Einhorn, MD, has been on the IU School of Medicine Department of Medicine faculty since 1973. His field of expertise includes clinical trials and supportive care, with focus in the areas of lung and testicular cancers. Dr. Einhorn has also been involved in the clinical development of new drug therapies. Studies chaired by Dr. Einhorn at IU School of Medicine in the area of testicular cancer led to the FDA approval of cisplatin, etoposide and ifosfamide. In addition, his groups conducted the pivotal studies that led to the approval of both gemcitabine and pemetrexed in non-small cell lung cancer. 

A major current area of focus for Dr. Einhorn is supportive care and survivorship, especially as it applies to patients who are cured with platinum-based chemotherapy for testicular cancer. He has been a long-standing member of the Multi-National Association for Supportive Care in Cancer (MASCC).

Dr. Einhorn's clinical interests include solid tumor oncology, specifically within the fields of genitourinary and lung cancers. His legacy will forever be linked with revolutionizing testicular cancer treatment. Prior to Dr. Einhorn's research in the area of platinum combination chemotherapy in patients with metastatic testicular cancer, the survival rate of the disease was approximately 10 percent. Now, due to Dr. Einhorn's monumental findings, the current survival rate for metastatic testicular cancer is at 80 percent. 

Dr. Einhorn rose to even greater prominence when he used his novel treatment paradigm to treat Lance Armstrong, cancer advocate and seven-time winner of the Tour de France. With Dr. Einhorn's treatment, Armstrong survived stage 3 testicular cancer that initially presented with abdominal, brain and lung metastases. Like Armstrong, Einhorn remains dedicated to raising cancer awareness. He was appointe the first Lance Armstrong Foundation professor of oncology in 2006.